期刊文献+

HPLC法测定索非布韦片的有关物质 被引量:3

Determination of related substances in sofosbuvir tablets by HPLC
下载PDF
导出
摘要 目的:建立索非布韦片有关物质的HPLC法。方法:采用Waters Symmetry C18(4.6 mm×150 mm,5μm)色谱柱,流动相为0.01 mol·L^(-1)磷酸二氢钠溶液(用磷酸调节pH至3.0)-乙腈(75∶25),流速为1.0 m L·min^(-1),检测波长为210 nm,柱温30℃,进样量20μL,对有关物质进行定量分析。结果:在该色谱条件下,索非布韦与各杂质均能有效分离,杂质A(中间体)、杂质B(起始原料)、杂质C(降解产物)的定量限分别为1.012、2.005、2.010 ng,且在各自的线性范围内线性关系良好(r>0.999,n=7),杂质加样回收率(n=9)在96.11%~102.20%之间,重复性、精密度、稳定性等符合规定。对3批索非布韦片进行有关物质测定,结果总杂质量在0.108%~0.129%范围内。结论:方法学验证结果表明,本法可作为索非布韦片有关物质的测定。 Objective: To establish an HPLC method for determination of the related substances in sofosbuvir tablets. Methods: The test was based on an Waters Symmetry C18(5μm,4.6×150mm) column. The mobile phase consisted of 0.01 mol.L-1 sodium dihydrogen phosphate(adjusted to pH 3.0 with phosphoric acid) -acetonitrile (75:25) at a flow rate of 1.0 mL.min-1 and the detection wavelength was 210 nm.The column temperature was 30 ℃,and the volume of injection was 20μL. The related substances were quantified by the established method. Results: Sofosbuvir was separated completely from the impurities at this chromatographic conditions. The limits of impurity A(intermediate), impurity B(material) and impurity C(degradation) were 1.012,2.005,2.010ng. The calibration curves of these impurities were linear in the self-concentration range(r〉0.999 ,n=7).The recoveries of these impurities (n=9) were between 96.11% and 102.20%. The repeatability ,intermediate precision and stability were completely met the requirements. The total impurities were 0.108%~0.129% in 3 batches of sofosbuvir tablets. Conclusion: Methodology validation results proved that the established determination method can be used for quality control of sofosbuvir tablets.
作者 贾首时 王萌萌 王超众 JIA Shoushi;WANG Mengmeng;WANG Chaozhong(Qiqihar Center for Disease Control and Prevention, Qiqihar 161000, China;No. 1 Hospital of Qiqihar, Department of Integrated Chinese and Western Medicine, Qiqihar 161005, Chin;Qiqihar Institute for Food and Drug Control, Qiqihar 161005, China)
出处 《中国药品标准》 CAS 2018年第1期38-43,共6页 Drug Standards of China
关键词 高效液相色谱法 索非布韦片 有关物质 方法学验证 质量控制 杂质 HPLC Sofosbuvir Tablets related substances methodology validation quality control impurities
  • 相关文献

参考文献4

二级参考文献16

  • 1Michael P Manns,Markus Cornberg.Sofosbuvir: the final nail in the coffin for hepatitis C?[J].The Lancet Infectious Diseases.2013(5)
  • 2PAWLOTSKY JM. Treatment of chronic hepatitis C: current and future[J]. Curr Top Microbiol Immunol, 2013, 369:321-342.
  • 3World Health Organization. Hepatitis C: fact sheet no.164. 2013.[EB/OL]. (2013-12-18) [2014-02-20]. http://www.who.int/mediacentre/factsheets/fs164/en/.
  • 4雷光宇.索非布韦激情引爆原料中间体[N]. 医药经济报, 2015-1-26(6).
  • 5PERRONE P, DAVERIO F, VALENTE R, et al. First example of phosphoramidate approach applied to a 4'-substituted purine nu- cleotide (4'-azidoadenosine) : conversion of an inactive nueleotide to a submieromolar compound versus hepatitis C virus[ J]. J Med Chem, 2007, 50(22): 5463-5470.
  • 6SOFIA MJ, BAO DH, CHANG W, et al. Discovery of a β-D-2'- Deoxy-2'-α-fluoro-2'-β-C-methyluridine nueleotide prodrug (PSI- 7977) for the treatment of hepatitis C virus [ J]. J Med Chem,2010, 53(19) : 7202 -7218.
  • 7MURAKAMI E, TOLSTYKH T, BAO H, et al. Mechanism of ac- tivation of PSI-7851 and its diastereoisomer PSI-7977 [ J]. J Biol Chem, 2010, 285(45): 34337-34347.
  • 8MCGUIGAN C, JONES BCNM, DEVINE KG, et al. Attempts to introduce chemotherapeutic nueleotides into cells: studies on the anti-HIV agent FDT[J]. Bioorg Meal Chem Lett, 1991, 1 (12) : 729 - 732.
  • 9MCGUIGAN C, PATHIRANA RN, BALZARINI J, et al. Intra- cellular delivery of bioaetive AZT nucleotides by aryl phosphate de- rivatives of AZT[ J]. J Med Chem, 1993, 36 (8) : 1048 - 1052.
  • 10MCGUIGAN C, CAHARD D, SHEEKA HM, et al. Phosphorami- date derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase deficient cells [ J ]. Bioorg Med Chem Lett, 1996, 6(10) : 1183 -1186.

共引文献18

同被引文献28

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部